VALCHLOR® (mechlorethamine) gel is an alkylating drug indicated for the topical treatment of Stage IA and IB mycosis fungoides–type cutaneous T-cell lymphoma (MF-CTCL) in patients who have received prior skin-directed therapy

The treatment for Stage IA/IB MF-CTCL that is

Artistic rendition of Stage IA/IB MF-CTCL. Not an actual patient.

*VALCHLOR (n=119) was assessed in a 12-month randomized, multicenter, observer-blinded, noninferiority study trial (N=260) vs Aquaphor®-based mechlorethamine HCl 0.02%. Primary endpoint: response by CAILS (Composite Assessment of Index Lesion Severity) score (combined scores for erythema, scaling, plaque elevation, and surface area). CAILS ORR: 60% (PR 45% + CR 14%). VALCHLOR noninferiority demonstrated by the rate ratio of 1.24 (95% CI, 0.98, 1.58). ORR (overall response rate) = PR (partial response) + CR (complete response, defined as a score of 0).1,2

VALCHLOR is the first and only FDA-approved topical form of mechlorethamine.1,3

A Clear Option
VALCHLOR copay program
Eligible patients pay
no more than $10 $0 per
prescription fill

References:

  1. VALCHLOR [package insert]. Iselin, NJ: Helsinn Therapeutics US, Inc.; January 2020.
  2. Lessin SR, Duvic M, Guitart J, et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. Arch Dermatol. 2012;E1-E8.
  3. Lymphoma Research Foundation. Getting the facts: cutaneous T-cell lymphoma. Lymphoma Research Foundation website. https://www.lymphoma.org/wp-content/uploads/2017/06/LRF_FACTSHEET_Cutaneous_TCell_Lymphoma_CTCL.pdf. Updated August 2017. Accessed November 19, 2018.